Clinical Edge Journal Scan

Risk factors for recurrence after hepatic resection for early-stage HCC


 

Key clinical point: Independent risk factors for postoperative recurrence among patients undergoing curative hepatic resection for early-stage hepatocellular carcinoma (HCC) include preoperative alpha-fetoprotein (AFP) level >400 µg/L, tumor size >5 cm, satellite nodules, multiple tumors, and microvascular invasion.

Major finding: Cirrhosis (adjusted hazard ratio [aHR] 1.49; P < .001), preoperative AFP level >400 µg/L (aHR 1.28; P = .004), tumor size >5 cm (aHR 1.74; P < .001), satellite nodules (aHR 1.35; P = .040), multiple tumors (aHR 1.63; P = .015), microvascular invasion (aHR 1.51; P < .001), and intraoperative blood transfusion (aHR 1.50; P = .013) were identified as independent risk factors associated with postoperative recurrence.

Study details: The data come from a large-scale, multicenter retrospective study including 1,424 adult patients who underwent curative hepatic resection for early-stage HCC (Barcelona Clinic Liver Cancer stage 0/A).

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors reported no conflict of interests.

Source: Yao L-Q et al. Clinical features of recurrence after hepatic resection for early-stage hepatocellular carcinoma and long-term survival outcomes of patients with recurrence: A multi-institutional analysis. Ann Surg Oncol. 2022 Feb 22. Doi: 10.1245/s10434-022-11454-y

Recommended Reading

Liver resection in HCC: Robot-assisted and laparoscopic vs. open
Federal Practitioner
Old age and liver stiffness on transient elastography may predict HCC occurrence after HCV eradication
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC March 2022
Federal Practitioner
Overall survival after curative resection for HBV-related HCC is better with tenofovir vs. entecavir
Federal Practitioner
Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCC
Federal Practitioner
LEN-TACE sequential therapy tops LEN monotherapy in unresectable HCC responsive to initial LEN treatment
Federal Practitioner
Meta-analysis underscores the need for improved HCC surveillance in NAFLD without cirrhosis
Federal Practitioner
Ramucirumab-mediated survival benefit in advanced HCC unperturbed by baseline prognostic covariates
Federal Practitioner
MRE-based shear strain mapping may preoperatively predict microvascular invasion in HCC
Federal Practitioner
Inadequate ultrasound quality negatively influences HCC surveillance test performance
Federal Practitioner